MYC as a therapeutic target for the treatment of triple-negative breast ...
MYC is one of the most frequently altered driver genes in triple-negative breast cancer (TNBC). The aim of this study was to evaluate targeting MYC for the treatment of TNBC. The anti-proliferative and apoptosis-inducing effects of the recently ...
MYC promotes immune-suppression in triple-negative breast
Nov 2, 2022 · MYC-mediated suppression of inflammatory signalling induced by BRCA1/2 inactivation is confirmed in human TNBC cell lines. Moreover, MYC overexpression prevents the recruitment and activation of...
MYC as a therapeutic target for the treatment of triple-negative breast ...
May 26, 2019 · Background: Despite intensive efforts, a validated targeted therapy for triple-negative breast cancer (TNBC) remains elusive. One of the most frequent genetic alterations identified in TNBC is amplification of the MYC gene which is found in > 60% of samples.
MYC-Driven Pathways in Breast Cancer Subtypes - PMC
In comparison to ER+ or HER2+ breast cancers, MYC expression is markedly elevated in TNBC along with altered expression of MYC regulated genes that potentiates MYC regulated pathways.
Targeting MYC for triple-negative breast cancer treatment
The MYC oncogene encodes for a transcription factor, c-Myc (MYC) that is overexpressed in multiple cancer types, including TNBC [2-4]. One of the mechanisms underlying the pro-tumor properties of MYC is likely its function in antagonizing oncogene activation-induced senescence [ …
Targeting MYCN-expressing triple-negative breast cancer with …
Mar 11, 2020 · We performed high-throughput chemical screens on TNBC cell lines with varying amounts of MYCN expression and determined that cells with higher expression of MYCN were more sensitive to bromodomain and extraterminal motif (BET) inhibitors.
MYC as a therapeutic target for the treatment of triple-negative breast ...
Our findings open the possibility of targeting MYC for the treatment of TNBC. Based on our results, we suggest that trials use a combination of MYCi975 and either docetaxel or doxorubicin and include MYC as a putative therapy predictive biomarker.
c-myc regulates the sensitivity of breast cancer cells to
Sep 15, 2020 · We quantified palbociclib sensitivity and c-myc expression in 11 breast cancer cell lines, 124 breast cancer samples, and The Cancer Genome Atlas database. We found non-TNBC subtypes were...
Combinatorial immunotherapies overcome MYC-driven immune
Jun 27, 2022 · Here, we report that TNBCs with elevated MYC expression are resistant to immune checkpoint inhibitor therapy. Using mouse models and patient data, we show that MYC signaling is...
MYC amplification sensitizes TNBC to CHK1 inhibitors
Mar 5, 2025 · Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, for which effective therapy is urgently needed. We demonstrated that MYC overexpression was associated with TNBC subtype and promoted the cell proliferation, invasion and migration in TNBC cells.